[{"address1": "88 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 649 8600", "website": "https://www.agios.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 383, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian M. Goff M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1458975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Jones", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 751482, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James William Burns", "age": 45, "title": "Corporate Secretary & Chief Legal Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1019942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Gheuens M.D., Ph.D.", "age": 43, "title": "Chief Medical Officer and Head of Research & Development", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 1247567, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsveta  Milanova", "age": 46, "title": "Chief Commercial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 939048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lewis Clayton Cantley Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.", "age": 77, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1946, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Craig B. Thompson M.D.", "age": 70, "title": "Co-Founder & Chairman of Scientific Advisory Board", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shin-San  Su Ph.D.", "age": 67, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. T. J. Washburn", "age": 41, "title": "Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 31.5, "open": 38.5, "dayLow": 37.41, "dayHigh": 39.7, "regularMarketPreviousClose": 31.5, "regularMarketOpen": 38.5, "regularMarketDayLow": 37.41, "regularMarketDayHigh": 39.7, "beta": 0.806, "forwardPE": -6.6917686, "volume": 2678710, "regularMarketVolume": 2678710, "averageVolume": 663488, "averageVolume10days": 570150, "averageDailyVolume10Day": 570150, "bid": 38.09, "ask": 38.29, "bidSize": 300, "askSize": 100, "marketCap": 2169296384, "fiftyTwoWeekLow": 19.8, "fiftyTwoWeekHigh": 39.7, "priceToSalesTrailing12Months": 73.77806, "fiftyDayAverage": 31.1594, "twoHundredDayAverage": 26.2627, "currency": "USD", "enterpriseValue": 1258704384, "floatShares": 47410536, "sharesOutstanding": 56773000, "sharesShort": 6082711, "sharesShortPriorMonth": 6653774, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1071, "heldPercentInsiders": 0.01459, "heldPercentInstitutions": 1.1060901, "shortRatio": 8.93, "shortPercentOfFloat": 0.1087, "impliedSharesOutstanding": 58917700, "bookValue": 13.108, "priceToBook": 2.9150138, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -352619008, "trailingEps": -6.31, "forwardEps": -5.71, "pegRatio": -0.18, "enterpriseToRevenue": 42.809, "enterpriseToEbitda": -3.254, "52WeekChange": 0.24407578, "SandP52WeekChange": 0.26137078, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AGIO", "underlyingSymbol": "AGIO", "shortName": "Agios Pharmaceuticals, Inc.", "longName": "Agios Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1374672600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "52f076ec-0de6-382e-b01b-3ddfa165dcb4", "messageBoardId": "finmb_46539787", "gmtOffSetMilliseconds": -14400000, "currentPrice": 38.21, "targetHighPrice": 49.0, "targetLowPrice": 33.0, "targetMeanPrice": 44.0, "targetMedianPrice": 45.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 597990976, "totalCashPerShare": 10.533, "ebitda": -386764992, "totalDebt": 68347000, "quickRatio": 11.635, "currentRatio": 12.838, "totalRevenue": 29403000, "debtToEquity": 9.187, "revenuePerShare": 0.526, "returnOnAssets": -0.24547, "returnOnEquity": -0.3961, "freeCashflow": -221808256, "operatingCashflow": -300745984, "revenueGrowth": 0.46, "operatingMargins": -11.243381, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-28"}]